GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Citius Oncology CTOR · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.55

+7.85%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Citius Oncology

From its filings with the US Securities and Exchange Commission

SEC filings

Citius Oncology is based in Cranford, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CTOR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 September 2025, it reported a net loss of $24.8m. At that date it held total assets of $100.9m and shareholders' equity of $44.9m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
14 Oct 2022
Head office
11 COMMERCE DRIVE, CRANFORD, NJ, 07016
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Leonard MazurExecutive Chairman of the Board, Chief Executive Officer, since 2024$3.8m
  • Mr. Myron HolubiakExecutive Vice Chairman of the Board, Secretary, Director, since 2024$2.2m
  • Mr. Jaime BartushakChief Financial Officer, Treasurer
  • Dr. Myron CzuczmanChief Medical Officer$2.0m
  • Mr. Joel MayersohnDirector, since 2022$726,626
  • Mr. Suren DutiaIndependent Director$620,813
  • Dr. Eugene HolukaIndependent Director$620,813
  • Mr. Dennis McgrathIndependent Director$620,813
  • Mr. Robert SmithIndependent Director$620,813
  • Ms. Carol WebbIndependent Director$620,813
  • Ms. Ilanit AllenVice President - Corporate Communications and Investor Relations, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in New York City, New York
  • Focused on developing and commercializing targeted oncology therapies
  • Lead product candidate LYMPHIR for treatment of CTCL

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No financial data provided for analysis
  • No market share or competitive position details

Opportunities

  • Development of LYMPHIR for CTCL treatment
  • Potential commercialization of targeted oncology therapies
  • Growth in biotechnology sector for oncology treatments

Threats

  • No specific threats mentioned in the provided information
  • No competitive landscape details provided
  • No regulatory challenges mentioned

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.